Haemonetics (HAE) Tops Q3 EPS by 18c, Revenues Beat; Raises FY20 EPS Guidance Above Consensus

Haemonetics (NYSE: HAE) reported Q3 EPS of $0.94, $0.18 better than the analyst estimate of $0.76. Revenue for the quarter came in at $259 million versus the consensus estimate of $255.4 million.

Q3 Earnings Letter PDF

GUIDANCE:

Haemonetics sees FY2020 EPS of $3.30-$3.40, versus the consensus of $3.18.

For earnings history and earnings-related data on Haemonetics (HAE) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
• Hydrofarm Holdings Group, Inc. (HYFM) Misses Q2 EPS by 134c